Skip to content

Trial Summary

A Phase 1, First-in-human Study of ARB202, Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies



ACTRN/NCT /ethics:


Scientific title:

Treatment of ARB202 Advanced Gastrointestinal Cancer Patients

Sponsor / Cooperative group:

Arbele Pty Ltd

Trial & Patient Characteristics

Cancer TypeGastrointestinal cancers
Trial TypeTreatment
PhasePhase I
Age Range18 years and older
Tumour Stream -
Cancer StageLocally Recurrent or Locally Advanced; Metastatic or Widespread
Anticipated Start Date2022-05-30
Anticipated End Date2025-08-01

Participating Hospitals

HospitalSouthern Oncology Clinical Research Unit
Clinical Trial CoordinatorMeggan O'Riley
Phone0491 679 039
Principal InvestigatorDr Ganessan Kichenadasse
Recruitment StatusRecruiting